R-120758, A Novel Triazole Antifungal Agent: In Vitro Antifungal Activity.
Background: The in vitro activity of R-120758, a novel triazole agent, was compared with those of the triazole drugs fluconazole (FLCZ) and itraconazole (ITCZ) and that of the polyene agent amphotericin B (AMPH-B). Methods: MICs against pathogenic fungi were determined by the broth microdilution method. R-120758 exhibited the strongest activity against the above species among the drugs tested. Against Candida albicans (7 strains) with low susceptibility to FLCZ (FLCZ MICs, 4 to 32 Âµg/ml), R-120758 exhibited good activity with MICs ranging from 0.016 to 0.5 Âµg/ml. The activity of R-120758 was very potent against Cryptococcus neoformans, Aspergillus fumigatus, and Aspergillus flavus, and it was 8 times as strong as that of ITCZ. R-120758 also exhibited potent activity against other Candida spp., other Aspergillus spp., and Trichosporon spp. Conclusion: R-120758 exhibited broad-spectrum and potent antifungal activity.
Full conference title:
Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy